The use of radiolabeled compounds for ADME studies in discovery and exploratory development

Current Pharmaceutical Design

Volumn 10, Issue 24, 2004, Pages 2991-3008

  Marathe, P H ^a   Shyu, W C ^a   Humphreys, William G ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Absorption; Bioavailability; Covalent binding; Mass balance; Metabolite profiling; Radiolabeled; Tissue distribution

Indexed keywords

3 (5 CHLORO 2 METHOXYPHENYL) 3 FLUORO 2,3 DIHYDRO 6 TRIFLUOROMETHYL 1H INDOL 2 ONE; 5 FLUORO 3 [3 [4 (5 METHOXY 4 PYRIMIDINYL) 1 PIPERAZINYL]PROPYL] 1H INDOLE; AMOXICILLIN; APAFANT; ATENOLOL; CARBAMAZEPINE; CARBON 14; CLARITHROMYCIN; DIDANOSINE; DIGOXIN; GLYCOPROTEIN P; IMIPRAMINE; KETOCONAZOLE; LANSOPRAZOLE; MACROGOL 4000; MANNITOL; METHOXSALEN; MULTIDRUG RESISTANCE PROTEIN 1; NEFAZODONE; OMAPATRILAT; PARACETAMOL; PHENCYCLIDINE; RADIOISOTOPE; TAMOXIFEN; THEOPHYLLINE; THROMBIN INHIBITOR; TIENILIC ACID; TRITIUM; UNINDEXED DRUG; VINBLASTINE;

AREA UNDER THE CURVE; BINDING AFFINITY; CELL STRAIN CACO 2; DOG; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG FECES LEVEL; DRUG METABOLISM; DRUG PENETRATION; DRUG RESEARCH; DRUG STRUCTURE; DRUG TRANSPORT; DRUG URINE LEVEL; HUMAN; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MEMBRANE PERMEABILITY; MONKEY; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOCHEMISTRY; RAT; REVIEW; TECHNOLOGY; TISSUE DISTRIBUTION;

ANIMALS; BIOLOGICAL AVAILABILITY; DRUG DESIGN; HUMANS; PHARMACEUTICAL PREPARATIONS; RADIOISOTOPES;

EID: 4544295323     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043383494     Document Type: Review

References (63)

1. Saljoughian M, Williams PG. Recent developments in tritium incorporation for radiotracer studies. Curr Pharm Des 2000; 6(10): 1029-56.
2. Hunter J, Jepson MA, Tsuruo T, Simmons NL, Hirst BH. Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells. Kinetics of vinblastine secretion and interaction with mudulators. J Biol Chem 1993; 268(20): 14991-14997.
3. Artursson P, Karlsson J. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun 1991; 175(3): 880-885.
4. Egnash LA, Ramanathan R. Comparison of heterogeneous and homogeneous radioactivity flow detectors for simultaneous profiling and LC-MS/MS characterization of metabolites. J Pharm Biomed Anal 2002; 27(1-2): 271-84.
5. Nassar AE, Bjorge SM, Lee DY. On-line liquid chromatography-accurate radioisotope counting coupled with a radioactivity detector and mass spectrometer for metabolite identification in drug discovery and development. Anal Chem 2003, 75(4): 785-90.
6. Guengerich FP, Cai H, Johnson WW, Parikh A. Reactive intermediates in biological systems: what have we learned and where are we going? Adv Exp Med Biol 2001; 500: 639-50.
7. Uetrecht J. Screening for the potential of a drug candidate to cause idiosyncratic drug reactions. Drug Discovery Today 2003; 8(18): 832-7.
8. Guengerich FP. Cytochrome P450 oxidations in the generation of reactive electrophiles: epoxidation and related reactions. Arch Biochem Biophys 2003; 409(1): 59-71.
9. Zhang D, Ogan M, Gedamke R, Roongta V, Dai R, Zhu M, et al. Protein covalent binding of maxipost through a cytochrome P450-mediated ortho-quinone methide intermediate in rats. Drug Metab Dispos 2003; 31(7): 837-45.
10. Samuel K, Yin W, Stearns RA, Tang YS, Chaudhary AG, Jewell JP, et al. Addressing the metabolic activation potential of new leads in drug discovery: a case study using ion trap mass spectrometry and tritium labeling techniques. J Mass Spectrom 2003; 38(2): 211-21.
11. Lecoeur S, Bonierbale E, Challine D, Gautier JC, Valadon P, Dansette PM, et al. Specificity of in vitro covalent binding of tienilic acid metabolites to human liver microsomes in relationship to the type of hepatotoxicity: comparison with two directly heptotoxic drugs. Chem Res Toxicol 1994; 7(3): 434-42.
12. Pirmohamed M, Kitteringham NR, Guenthner TM, Breckenridge AM, Park BK. An investigation of the formation of cytotoxic, protein-reactive and stable metabolites from carbamazepine in vitro. Biochem Pharmacol 1992; 43(8): 1675-82.
13. Pirmohamed M, Kitteringham NR, Breckenridge AM, Park BK. The effect of enzyme induction on the cytochrome P450-mediated bioactivation of carbamazepine by mouse liver microsomes. Biochem Pharmacol 1992; 44(12): 2307-14.
14. Masubuchi Y, Igarashi S, Suzuki T, Horie T, Narimatsu S. Imipramine-induced inactivation of a cytochrome P450 2D enzyme in rat liver microsomes: in relation to covalent binding of its reactive intermediate. J Pharmacol Exp Ther 1996; 279(2): 724-31.
15. Mays DC, Hilliard JB, Wong DD, Chambers MA, Park SS, Gelboin HV, et al. Bioactivation of 8-methoxypsoralen and irreversible inactivation of cytochrome P-450 in mouse liver microsomes: modification by monoclonal antibodies, inhibition of drug metabolism and distribution of covalent adducts. J Pharmacol Exp Ther 1990; 254(2): 720-31.
16. Singh R, Silva Elipe MV, Pearson PG, Arison BH, Wong BK, White R, et al. Metabolic activation of a pyrazinone-containing thrombin inhibitor. Evidence for novel biotransformation involving pyrazinone ring oxidation, rearrangement, and covalent binding to proteins. Chem Res Toxicol 2003; 16(2): 198-207.
17. Ward DP, Trevor AJ, Kalir A, Adams JD, Baillie TA, Castagnoli N Jr. Metabolism of phencyclidine. The role of iminium ion formation in covalent binding to rabbit microsomal protein. Drug Metab Dispos 1982; 10(6): 690-5.
18. 14C] tamoxifen to liver microsomes and the forms of cytochrome P450 involved. Biochem Pharmacol 1995, 49(8): 1035-42.
19. Chen WG, Zhang C, Avery MJ, Fouda HG. Reactive metabolite screen for reducing candidate attrition in drug discovery. Adv Exp Med Biol 2001, 500: 521-4.
20. Turteltaub KW, Vogel JS. Bioanalytical applications of accelerator mass spectrometry for pharmaceutical research. Curr Pharm Des 2000, 6(10): 991-1007.
21. Garner, RC. Accelerator mass spectrometry in pharmaceutical research and development - a new ultrasensitive analytical method for isotope measurement. Curr Drug Metab 2000; 1(2): 205-13.
22. Young G, Ellis W, Ayrton J, Hussey E, Adamkiewicz B. Accelerator mass spectrometry (AMS): recent experience of its use in a clinical study and the potential future of the technique. Xenobiotica 2001; 31(8-9): 619-32.
23. Garner RC, Goris I, Laenen AA, Vanhoutte E, Meuldermans W, Gregory S, et al. Evaluation of accelerator mass spectrometry in a human mass balance and pharmacokinetic study-experience with 14C-labeled (R)-6-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4- (3-chlorophenyl)-1-methyl-2(1H)-quinolinone (R115777), a farnesyl transferase inhibitor. Drug Metab Dispos 2002; 30(7): 823-30.
24. Combes RD, Berridge T, Connelly J, Eve MD, Garner RC, Toon S, et al. Early microdose drug studies in human volunteers can minimise animal testing: Proceedings of a workshop organised by Volunteers in Research and Testing. Eur J Pharm Sci 2003; 19(1): 1-11.
25. Lappin G, Garner RC. Big physics, small doses: the use of AMS and PET in human microdosing of develogment drugs. Nat Rev Drug Discov 2003; 2(3): 233-40.
26. 13C(2 ]omapatrilat after oral administration to rats, dogs, and humans. Drug Metab Dispos 2003; 31(1):67-75.
27. Baillie TA. Chemically reactive metabolites in drug discovery and development. In Drug Metabolizing Enzymes (eds. Lee, JS, et al.), FontisMedia S.A.
28. Schinkel AH, Mayer U, Wagenaar E, Mol CA, Van Deemter L, Smit JJ, et al. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoprotein. Proc Nat Acad Sci USA 1997; 94(8): 4028-4033.
29. Schinkel AH, Smit JJ, Van Tellingen O, Beijnen JH, Wagenaar E, Van Deemter L, et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994; 77(4): 491-502.
30. Leusch A, Volz A, Muller G, Wagner A, Sauer A, Greischel A, et al. Altered drug disposition of the platelet activating factor antagonist apafant in mdr1a knockout mice. Eur J Pharm Sci 2002; 16(3): 119-128.
31. Goralski KB, Hartmann G, Piquette-Miller M, Renton KW. Downregulation of mdr1a expression in the brain and liver during CNS inflammation alters the in vivo disposition of digoxin. Br J Pharmacol 2003; 139(1): 35-48.
32. Schinkel AH, Wagenaar E, Van Deemter L, Mol CA, Borst P. Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 1995; 96(4): 1698-1705.
33. 14C]clarithromycin into gastric tissue in rats. Antimicrob Agents Chemother 2001; 45(12): 3451-3455.
34. 18F-labeled fluconazole in rabbits with candidal infections studied with positron emission tomography. J Pharmacol Exp Ther 1991; 259(3): 1351-1359.
35. 18F]fleroxacin in patients with acute exacerbations of chronic bronchitis and complicated urinary tract infection studies with positron emission tomography. Antimicrob Agents Chemother 1996; 40(3): 659-664.
36. Fowler JS, Volkow ND, Wolf AP. Positron emission tomography, enzymes and drug research and development and approval (eds. Burns HD, Gibson R, Danna R and Siegl P), Birthauser, Boston, 1993.
37. Boles Ponto LL, Ponto JA. Uses and limitations of positron emission tomography in clinical pharmacokinetics/pharmacodynamics. Clin Pharmacokin 1992; 22: Part II, 274-283.
38. Christian BT, Livni E, Babich JW, Alpert AM, Dishino DD, Ruediger E, et al. Evaluation of cerebral pharmacokinetics of the novel antidepressant drug, BMS-181101, by positron emission tomography. J Pharmacol Exp Ther 1996; 279(1): 325-331.
39. Takakura Y, Fujita T, Hashida M, Sezaki H. Disposition characteristics of macromolecules in tumor-bearing mice. Pharm Res 1990; 7(4): 339-346.
40. 14C]nefazodone in humans. Drug Metab Dispos 1996; 24(1): 91-95.
41. 14C]nefazodone in the dog. Drug Metab Dispo 1993; 21(3): 502-507.
42. 14C]omapatrilat in healthy subjects. J Clin Pharmacol 2001; 41(8): 833-841.
43. 14C]didanosine in the beagle dog. Drug Metab Dispo 1993; 21(3): 447-453.
44. Vachharajani NN, Shyu WC, Shah VR, Barbhaiya RH. Pharmacokinetic assessment of the sites of first-pass metabolism of BMS-181101, an antidepressant agent, in rats. J Pharm Pharmacol 1998; 50(3): 275-278.
45. Humphreys WG, Obermeier MT, Chong S, Kimball SD, Das J, Chen P, et al. Oxidative activation of acylguanidine prodrugs: Intestinal presystemic activation in rats limits absorption and can be inhibited by co-administration of ketoconazole. Xenobiotica 2003; 33(1): 93-106.
46. Krishna R, Yao M, Srinivas NR, Shah V, Pursley JM, Arnold M, et al. Disposition of radilabeled BMS-204352 in rats and dogs. Biopharmaceutics Drug Disp 2002; 23(1): 41-46.
47. Dockens RC, Santone KS, Mitroka JG, Morrison RA, Jemal M, Greene DS, et al. Disposition of radiolabeled ifetroban in rats, dogs, monkeys, and humans. Drug Metab Disp 2000; 28(8): 973-980.
48. Walle T, Walle K, Kumar GN, Bhalla KN. Taxol metabolism and disposition in cancer patients. Drug Metab Dispo 1995; 23(4): 506-512.
49. Leusch A, Eichhorn B, Busch U, Ensinger HA. Pharmacokinetics of pinokalant, a new nonselective cation channel blocker in the rat. Arzneim Forsch Drug Res 2001; 51(II): 947-954.
50. Maeshiba Y, Takeuchi T, Kondo T, Yamashita K, Tsukunda R, Yoshimura Y. Disposition of TAK-044, a new endothelin antagonist, in rats and dogs. Arzneim Forsch Drug Res 2002; 52(8): 587-592.
51. Giri SN, Wang Q, Xie Y, Lango J, Morin D, Margolin SB, et al. Pharmacokinetics and metabolism of a novel antifibrotic drug pirfenidone, in mice following intravenous administration. Biopharm Drug Dispos 2002; 23(5): 203-11.
52. Marathe PH, Greene DS, Barbhaiya RH. Disposition of [14C]avitriptan in rats and humans. Drug Metab Dispos 1997; 25(7): 881-8.
53. Ings RM, Breen M, Devereux K, Gray AJ, Edwards FE, Lucas C, et al. The comparative disposition of [14C]-fotemustine in non-tumourous and tumourous mice. Cancer Chemother Pharmacol 1990; 27(2): 106-10.
54. Kestell P, Paxton JW, Evans PC, Young D, Jurlina JL, Robertson IG, et al. Disposition of amsacrine and its analogue9-[(2-methoxy-4-[(methylsulfonyl)amino]phenyl]amino)- N,5-dimethyl-4-acridinecarboxamide (CI-921) in plasma, liver, and Lewis lung tumors in mice. Cancer Res 1990; 50(3): 503-8.
55. Arnold ST, Jayaram HN, Harper GR, Litterst CL, Malspeis L, DeSouza JJ, et al. The disposition and metabolism of tiazofurin in rodents, rabbits, and dogs. Drug Metab Dispos 1984; 12(2): 165-73.
56. Stuben J, Port R, Bertram B, Bollow U, Hull WE, Schaper M, et al. Pharmacokinetics and whole-body distribution of the new chemotherapeutic beta-D-glucosylisophosphoramide mustard and its effects on the incorporation of [methyl-3H]-thymidine in various tissues of the rat. Cancer Chemother Pharmacol 1996; 38(4): 355-65.
57. Jajoo HK, Mayol RF, LaBudde JA, Blair IA. Metabolism of the antianxiety drug buspirone in human subjects. Drug Metab Dispos 1989; 17(6): 634-40.
58. Mayol RF, Cole CA, Luke GM, Colson KL, Kerns EH. Characterization of the metabolites of the antidepressant drug nefazodone in human urine and plasma. Drug Metab Dispos 1994; 22(2): 304-11.
59. Scarfe GB, Lindon JC, Nicholson JK, Martin P, Wright B, Taylor S, et al. Investigation of the metabolism of 14C/13C-practolol in rat using directly coupled radio-HPLC-NMR-MS. Xenobiotica 2000; 30(7): 717-29.
60. Black AE, Hayes RN, Roth BD, Woo P, Woolf TF. Metabolism and excretion of atorvastatin in rats and dogs. Drug Metab Dispos 1999; 27(8): 916-23.
61. Hutchinson OC, Collingridge DR, Barthel H, Price PM, Aboagye EO. Pharmacokinetics of radiolabelled anticancer drugs for positron emission tomography. Curr Pharm Design 2003; 9(11): 917-29.
62. Lindvall MK. Molecular modeling in cysteine protease inhibitor design. Curr Pharm Design 2002; 8(18): 1673-81.
63. Uludag H. Bisphosphonates as a foundation or drug delivery to bone. Curr Pharm Design 2002; 8(21): 1929-44.